nivolumab,4sc-202,ipilimumab
4sc,bms
['donimi']
reijers et al. report that, in the donimi trial, a baseline ifn- signature enables prospective selection of patients who can benefit from anti-pd-1 monotherapy. from our #cancer collection: #aacr23 
The Journal of Experimental Medicine publishes immunology, cancer, stem cells, microbial pathogenesis, vascular biology, neurobiology. Est. 1896 - @RockUPress